Accendra Health brings the hospital home

A CPAP machine is a peculiar sort of purchase. It comes with a mask, a hose, instructions, and a question that the box cannot answer: how does this become part of somebody’s life? Apria’s welcome program offers a clue. Patients prepare for a setup call with their equipment nearby and an electrical outlet within reach. A sleep coach helps them get started. The treatment has been prescribed. Now comes the business of making it usable.

A machine is only the beginning

That gap between receiving a device and managing a condition is where Accendra Health operates. Its Apria and Byram Healthcare brands supply oxygen equipment, sleep therapy devices, diabetes supplies, ostomy products, wound care materials, and other essentials. The customers are people living with acute and chronic conditions, along with the clinicians and home health agencies arranging their care. The company says its brands serve more than three million patients annually.

The distinction between the two brands is useful. Apria, founded in 1995, concentrates on equipment and clinical support, including respiratory care, sleep apnea, and negative pressure wound therapy. Byram, established in 1968, specializes in supplies and education for conditions including diabetes, urology, and ostomy. A machine can require setup and ongoing support. A consumable needs to arrive again. Both impose work on a household already managing an illness.

Accendra’s expertise includes the less photogenic tasks: coordinating prescribed products, supporting patients, and navigating reimbursement. Its market includes national equipment suppliers such as AdaptHealth and Lincare, as well as regional operators. Accendra’s pitch rests on the breadth of two complementary businesses and a nationwide service network. Those are capabilities a referring practice or insurer can use; they do not establish that every patient will receive better service.

The company that sold its old name

The surprising part is how this home care company came into focus. Its predecessor, Owens & Minor, had a history reaching back to 1882. In 2017, it acquired Byram for approximately $380 million. In March 2022, it bought Apria for approximately $1.6 billion, using debt and cash. The pieces of a substantial home care operation were assembled inside a company also serving hospitals.

Then, on December 31, 2025, the parent completed the sale of its Products & Healthcare Services business to Platinum Equity for $375 million in cash, subject to adjustments, while retaining a five percent equity interest. The transaction included the Owens & Minor brand. The remaining public company became Accendra Health. Apria and Byram kept their names. The old corporate identity went out with the business being sold.

The new name began trading under ACH on January 2, 2026. For a patient ordering supplies, the familiar brand could remain the same. For the parent, the allocation problem had changed: its strategy and resources could concentrate on home-based care. That is the substantive decision underneath the rebrand. A logo cannot make that decision for you.

An $80 million change of plan

Before the split, there had been another idea for expansion. Owens & Minor agreed to acquire Rotech, another home medical equipment provider. In June 2025, the companies terminated the deal. Owens & Minor paid $80 million under the agreement. It had spent months working through the regulatory process, only to conclude that obtaining clearance was no longer a viable route.

“the path to obtain regulatory clearance for this merger proved unviable in terms of time, expense, and opportunity”Ed Pesicka · June 2025

That explanation matters because it identifies what failed first: the route to completing the acquisition. The company did not abandon home care. It abandoned that transaction and said it would focus on reducing debt and profitable growth. The fee gives the reversal a concrete cost. It also cautions against reading every strategic pivot as a tidy sequence planned from the beginning.

The person who needs it. The institution that pays.

There is another complication inside the home care model. The user and the payer are often different parties. Accendra sells or rents equipment and supplies; insurers and government programs help fund the care, with patients also contributing. Some arrangements pay for individual services. Others have used a monthly payment for covered members. Access therefore depends on more than having a warehouse full of useful products.

A major commercial payer’s contract exit made that dependency painfully visible. In August 2026, Accendra reported second-quarter revenue of $613.2 million, down from $681.9 million a year earlier, and a GAAP loss from continuing operations of $89.1 million. Management also reported a $385 million debt reduction during the quarter. Progress on the balance sheet was happening alongside pressure on the operating business.

The response included removing more than $125 million of annualized operating expense associated with the exited payer. There was also a new channel: Apria and Byram joined Optum Health’s preferred equipment network through an agreement effective September 2025. A new agreement creates access to referrals. It does not, by itself, replace lost sales or prove that the recovery has arrived.

What follows the delivery

Accendra now lists Kenneth Gardner-Smith as president and chief executive, succeeding Pesicka. He inherits a clearer business perimeter and the job of making its economics work. For other operators, the transferable idea is to build around the practical obstacles surrounding a product: setup, replenishment, education, and payment. The condition is equally plain. If insurer access disappears or reimbursement cannot cover service costs, a useful offering can still struggle financially.

For patients and caregivers, the route into this business is through Apria or Byram, often with a referring clinician. The sensible questions concern the prescribed item, insurance participation, likely personal cost, setup help, and how repeat orders work. Those details turn a national corporate strategy into something a household can judge. The next delivery, and the help that follows it, is where the promise gets tested.